Strengthening its leadership in diabetes care, USV Pvt. Ltd. has announced the launch of its Xenia brand range, following the ...

Kolkata: The National Pharmaceutical Pricing Authority (NPPA), in an order dated March 27, changed the prices of 80 medicines ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Rajeev Juneja, Vice-Chairman and Managing Director, Mankind Pharma (Image Credits: FE.com) Boehringer Ingelheim’s blockbuster diabetes Drug Empagliflozin is now off-patent in India. On Wednesday ...

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed prices of 80 new drugs including anti-diabetes, anti-hypertension, pain relief formulations from major pharmaceutical companies, in its ...